Back to all Current clinical trials
Back to all Current clinical trials
RC-48
The trial is testing a potential new treatment called disitamab vedotin for Muscle-invasive Bladder Cancer.
- Category
-
Trial status
Recruiting
-
Trial phase
Phase 2 Drug TrialEarly stage studies investigating efficacy and safety compared to standard therapies, as well as final dose determination in moderate sized patient cohorts.
- Registry listing
-
ERM Project ID
89018
Trial contact details
-
Contact person
Caitlin Bennett
-
Phone
07 3163 7689
What you need to know
Who can take part?
Patients with locally confined or Metastatic muscle invasive bladder cancer.
What is involved for you?
All patients in this trial will receive the investigational product via an IV infusion every two weeks. As part of each clinic visit, blood will be taken, a physical exam will be conducted and an ECG will be performed.
All research clinical trials news
-
News
Celebrating Excellence: Mater’s 2024 Publication of the Year Winners
-
News
Study aims to fight Inflammatory Bowel Disease with Aussie seafood
-
News
PhD student secures fellowship to pioneer mRNA vaccine for rare blood disorder
-
News
Clinical trials give hope to current and future breast cancer patients